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ORIGINAL ARTICLE
Systemic TLR2 agonist exposure regulates hematopoietic stem
cells via cell-autonomous and cell-non-autonomous
mechanisms
AC Herman1, DA Monlish1, MP Romine, ST Bhatt, S Zippel and LG Schuettpelz
Toll-like receptor 2 (TLR2) is a member of the TLR family of receptors that play a central role in innate immunity. In addition
to regulating effector immune cells, where it recognizes a wide variety of pathogen-associated and nonpathogen-associated
endogenous ligands, TLR2 is expressed in hematopoietic stem cells (HSCs). Its role in HSCs, however, is not well understood.
Furthermore, augmented TLR2 signaling is associated with myelodysplastic syndrome, an HSC disorder characterized by ineffective
hematopoiesis and a high risk of transformation to leukemia, suggesting that aberrant signaling through this receptor may have
clinically signiﬁcant effects on HSCs. Herein, we show that systemic exposure of mice to a TLR2 agonist leads to an expansion of
bone marrow and spleen phenotypic HSCs and progenitors, but a loss of HSC self-renewal capacity. Treatment of chimeric animals
shows that these effects are largely cell non-autonomous, with a minor contribution from cell-autonomous TLR2 signaling, and are
in part mediated by granulocyte colony-stimulating factor and tumor necrosis factor-α. Together, these data suggest that TLR2
ligand exposure inﬂuences HSC cycling and function via unique mechanisms from TLR4, and support an important role for TLR2
in the regulation of HSCs.
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INTRODUCTION
Toll-like receptors (TLRs) are pattern recognition receptors that
play a central role in innate immunity. Recent reports suggest
that TLR signaling regulates not only effector immune cells, but
may also inﬂuence hematopoietic stem cells (HSCs). HSCs express
multiple TLRs,1,2 and in vitro exposure to TLR agonists stimulates
HSC cycling and skews HSC differentiation toward the myeloid
lineage.1–3 Furthermore, chronic treatment of mice with the TLR4
agonist lipopolysaccharide leads to HSC cycling and expansion,
but decreased repopulating activity.4,5 Together, these studies
suggest that TLR signaling may shape the immune response from
the level of the HSC, regulating the proliferation, differentiation
and activity of these cells, and chronic exposure to TLR signals
may impair HSC function.
Although accumulating reports support a role for TLR signaling
in regulating HSCs, the mechanism of these effects is not clear.
TLRs are expressed on many hematopoietic and stromal cell
types, and therefore systemic TLR ligand exposure could have direct
or indirect effects on HSCs. Indeed, proinﬂammatory cytokines are
produced by effector immune cells and hematopoietic progenitors
in response to TLR ligands,6 and such cytokines themselves can
inﬂuence HSC cycling and function.7 In addition, it is not known
whether HSCs respond similarly to stimulation of different TLRs.
The existing literature has largely focused on TLR4, with recent
studies showing that TLR4 ligation indirectly promotes HSC
mobilization via production of granulocyte colony-stimulating factor
(G-CSF) by endothelial cells.8,9 It is not clear how stimulation of other
TLR family members affects HSCs, and whether they similarly
promote G-CSF-mediated HSC mobilization.
In this study, we sought to elucidate the effects of systemic
TLR2 ligand exposure on HSCs and determine the cell-autonomous
versus non-autonomous effects of such exposure. We speciﬁcally
focused on TLR2 signaling, as although TLR2 is expressed on
HSCs,1,10 its role in regulating these cells is not clear. Furthermore,
multiple studies have identiﬁed increased TLR expression and
signaling (particularly TLR2) in the CD34+ cells of patients with
myelodysplastic syndromes (MDS), a group of hematopoietic
stem cell disorders associated with ineffective hematopoiesis and
a high risk of leukemic transformation.11–15 This fact supports the
idea that TLR2 may regulate HSCs, and aberrant signaling through
this receptor may have clinically signiﬁcant effects on HSCs. In fact,
a clinical trial using a TLR2 antagonist for the treatment of patients
with MDS is currently underway (Opsona Therapeutics, Dublin,
Ireland), and thus an understanding of the role of TLR2 signaling in
regulating HSCs is highly relevant toward advancing therapy for
patients with MDS.
We and others previously reported that TLR2 is not necessary
for HSC function (in fact, loss of TLR2 leads to improved bone
marrow repopulating activity).16,17 Herein, we show that augmented
TLR2 signaling via exposure of mice to the TLR2 agonist, PAM3CSK4,
leads to an expansion of phenotypic bone marrow and spleen
hematopoietic stem and progenitors (HSPCs), but a loss of bone
marrow HSC function. Treatment of chimeric animals demonstrates
that these effects are largely cell non-autonomous. Given the known
role of G-CSF in mobilizing HSCs in response to TLR4 agonist,8
we assessed the contribution of G-CSF to the effects of PAM3CSK4
treatment on HSCs. Whereas PAM3CSK4 treatment is associated with
increased serum G-CSF levels, loss of G-CSF signaling only partially
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mitigates the agonist-induced effects on HSCs. Further studies
demonstrated that tumor necrosis factor-α (TNFα) signiﬁcantly
contributes to the TLR2 agonist-mediated cycling and expansion of
spleen HSCs. Notably, inhibition of G-CSF in chimeric mice revealed
a cell-autonomous role for TLR2 signaling in expanding pheno-
typic HSCs as well. Together, these data demonstrate that systemic
exposure to a TLR2 ligand inﬂuences HSCs via both cell-autonomous
and non-autonomous mechanisms, and reveal key differences
between the effects of different TLR agonists on HSCs.
MATERIALS AND METHODS
Mice
C57BL/6J (CD45.2), C57BL/6 mice (B6.SJL-Ptprc* Pep3b BoyJ) carrying
the CD45.1 allele, Tlr2−/− (B6.129-Tlr2tm1Kir/J), Ifnγ−/− (B6.129S7-Ifngtm1Ts/J),
Tnfα−/− (B6.129S-Tnftm1Fkl/J), Cxcr5−/− (B6.129S(Cg)-Cxcr5tm1Lipp/J) and Ccl2−/−
(B6.129S4-Ccl2tm1Rol/J) mice were obtained from the Jackson Laboratory (Bar
Harbor, ME, USA). Csf3r−/− mice were a gift of Dr Daniel Link (Washington
University, St Louis, MO, USA). All mice were maintained on a C57BL/6J
background. Sex- and age-matched mice were used in accordance with the
guidelines of the Washington University Animal Studies Committee.
TLR2 agonist and cytokine neutralizing antibody injections
PAM3CSK4 and PAM2CSK4 (Invivogen, San Diego, CA, USA) were
reconstituted in sterile water and delivered by intraperitoneal injection.
Unless otherwise indicated, mice were given 100 μg per dose, every
48 h× 3 doses and analyzed 24 h after the ﬁnal dose. For experiments
involving G-CSF and/or TNFα neutralization, 150 μg of G-CSF neutralizing
antibody (clone 67604, R&D Systems, Minneapolis, MN, USA), 100 μg of
TNFα neutralizing antibody (clone MP6-XT22, Biolegend, San Diego, CA,
USA) or isotype control (clone 43414, R&D Systems) were injected
intraperitoneally 90 min before each PAM3CSK4 injection.
Flow cytometry for HSPC and chimerism analysis
Peripheral blood was obtained by retro–orbital venous plexus sampling.
Bone marrow was isolated by centrifugation of leg bones at 3300 g for
1 min. Spleen cells were harvested by crushing through a 100 μM strainer.
Cells were processed as previously described,18 and stained using the
antibodies listed in Supplementary Materials. Cell counts were determined
using a Countess automated cell counter (Invitrogen, Carlsbad, CA, USA).
Stained cells were analyzed on a BD ﬂow cytometer (BD, Franklin Lakes,
NJ, USA) or the Gallios ﬂow cytometer (Beckman Coulter, Indianapolis,
IN, USA). Data were analyzed with FlowJo software (version 9.7; TreeStar,
Ashland, OR, USA).
Cell cycle analysis
For Ki-67 staining, bone marrow or spleen cells were stained for surface
markers (see Supplementary Materials), ﬁxed using the BD cytoﬁx/cytoperm
kit (BD), blocked with 5% goat serum, stained with mouse anti-human
Ki-67 (clone B56; BD Pharmingen, San Diego, CA, USA), washed and
resuspended in DAPI (4',6-diamidino-2-phenylindole)-containing FACS buffer.
For analysis of 5-bromodeoxyuridine (BrdU) incorporation, mice were
injected with BrdU (1 mg intraperitoneally q12h×4 doses) starting 48 h
before cell harvest. Cells were stained for surface markers, and then ﬁxed and
stained for anti-BrdU using the FITC BrdU ﬂow kit (BD) according to the
manufacturer’s instructions.
Long-term repopulating assays
For transplants involving sorted HSCs, bone marrow cells were obtained
by crushing bones in phosphate-buffered saline with 0.1% bovine
serum albumin. Spleens were gently crushed. Cells were ﬁltered and
stained using the panel of antibodies described in Supplementary
Materials. c-Kit+ cells were enriched before sorting by selection with
biotin-conjugated beads (Miltenyi Biotec, San Diego, CA, USA). Non-viable
cells were excluded by DAPI staining. Twenty KSL SLAM donor HSCs
were transplanted via retro–orbital injection, in addition to 3 00 000
recipient-type whole bone marrow support cells, into lethally irradiated
recipient mice (2 doses of 550 cGy spaced 4 h apart). For whole bone
marrow and whole spleen cell transplants, 1 × 106 bone marrow cells
or 2 × 106 spleen cells were transplanted along with 1 × 106 bone marrow
competitor cells into irradiated recipients.
Chimera generation
Chimeric mice were generated by transplanting a 1:1 mixture of whole
bone marrow cells from wild-type (WT) and Tlr2−/− donors into either WT
or Tlr2−/− recipients, as indicated. For Figure 4, WT or Tlr2−/− bone marrow
was transplanted alone into either WT or Tlr2−/− recipients. A total of
2 × 106 cells were injected retro–orbitally into lethally irradiated recipients.
In all cases, cells were allowed to engraft for at least 11 weeks before
treatment, and peripheral blood sampling of all chimeras was done before
further analyses to ensure equal engraftment.
Homing assay
2× 106 whole bone marrow cells were harvested from WT CD45.2 mice
treated with PAM3CSK4 (100 μg per dose, every 48 h× 3 doses) or water
alone and transplanted via retro–orbital injection into lethally irradiated
WT CD45.1 mice. After 16 h, long bones were harvested (pelvis, femur, tibia
and humerii), crushed, ﬁltered and stained for ﬂow cytometry.
Cytokine measurements
Bone marrow was isolated by centrifugation of femurs and spleens
were crushed through a 100 μm strainer. The total protein concentration
was determined using the BCA Protein Assay (Pierce, Rockford, IL, USA).
Blood was harvested by cardiac puncture, allowed to clot for 2 h, then
spun for 10 min at 3300 g. Cytokine levels were determined using the
Mouse Cytokine Array Panel A (R&D Systems) following the manufacturer’s
instructions. Membranes were exposed to X-ray ﬁlm, and signal intensities
were quantiﬁed with ImageJ (NIH, Bethesda, MD, USA). Serum G-CSF and
TNFα levels were also measured using the mouse G-CSF quantikine
enzyme-linked immunosorbent assay (ELISA) kit and the mouse TNFα
quantikine ELISA kit, respectively (R&D Systems), following the manufac-
turer’s instructions.
Colony forming units in culture assay
A total of 50 000 spleen cells were plated in MethoCult GF M3434
(Stem Cell Technologies, Vancouver, BC, Canada). Colonies were scored
after 7 days of growth at 37 °C in a humidiﬁed chamber with 5% CO2.
Statistical analysis
Data are presented as mean± s.e.m., unless otherwise stated. Statistical
signiﬁcance was assessed using an unpaired, two-tailed Student’s t-test
or two-sided analysis of variance. Repopulating unit calculations were
determined using the equation: RU= ([%chimerism of test donor-derived
cells] × [no. of competitor cells] × 10− 5)/%chimerism of competitor-derived
cells.19
RESULTS
TLR2 agonist treatment leads to expansion of bone marrow
phenotypic HSCs but loss of BM repopulating activity
TLR2 functions as a heterodimer with TLR1 or TLR6.20 To determine
the effects of systemic TLR2 agonist exposure on HSCs, WT mice
were treated with the TLR1/2 agonist PAM3CSK4 (3 doses of 100 μg
intraperitoneally every other day). Bone marrow and spleen cells
were harvested 24 h following the ﬁnal dose and analyzed by ﬂow
cytometry (Supplementary Figure 1). We observed a modest increase
in the frequency of bone marrow HSCs (c-Kit+ Sca-1+ Lineage−
CD150+ CD48− cells, ‘KSL SLAM’ or c-Kit+ Lineage− CD150+
CD48− ) and a decrease in megakaryocyte–erythroid progenitors
(c-Kit+ Sca-1− Lineage− CD34− CD16/32− ; Figures 1a and b and
Supplementary Figure 1) in agonist-treated mice compared with
controls. To determine HSC function, competitive repopulating assays
were performed in which whole bone marrow from PAM3CSK4- or
water control-treated mice was transplanted in a 1:1 ratio with
untreated competitor marrow into lethally irradiated recipients.
The bone marrow from PAM3CSK4-treated mice showed impairment
in B220+ (B cell) engraftment in primary recipients (Figure 1c). To test
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HSC self-renewal, bone marrow from the primary recipients was
transplanted into secondary recipient mice. Peripheral blood
sampling of the secondary recipients showed a signiﬁcant reduction
in test donor chimerism from the PAM3CSK4-treated group versus
controls (Figure 1d), demonstrating reduced HSC self-renewal.
Finally, to assess HSPC homing, 2×106 whole bone marrow cells
from PAM3CSK4-treated WT (CD45.2) mice or water-treated controls
were injected into lethally irradiated CD45.1 recipients and KSL cells
were enumerated 16 h later (Figure 1e). We found no difference
in the number of homed donor cells between the groups, suggesting
that the loss of HSC function upon PAM3CSK4 treatment cannot
be explained by lack of HSPC homing.
TLR2 signaling leads to expansion of spleen HSPCs
The spleens of PAM3CSK4-treated mice were signiﬁcantly enlarged
(Figures 2a and b) and had a marked increase in HSPC populations
(Figures 2c and d and Supplementary Figure 1). Cell cycle analysis of
spleen HSCs using either Ki-67 and DAPI or BrdU incorporation
demonstrated that, in contrast to the bone marrow, the KSL SLAM
cells in the spleen were signiﬁcantly less quiescent upon PAM3CSK4
treatment (Figures 2e and f and Supplementary Figure 2), suggesting
that local proliferation (as opposed to mobilization alone) may
contribute to this expansion. Consistent with the increased myeloid
progenitors seen by ﬂow cytometry, the spleens of PAM3CSK4-
treated mice displayed a marked increase in progenitor colony
formation in methylcellulose (Figure 2g). Treatment with lower doses
of PAM3CSK4 demonstrated that this expansion of HSPCs is dose
dependent (Supplementary Figure 3). Treatment with the speciﬁc
TLR2/6 agonist PAM2CSK4 produced similar results, with expansion of
bone marrow and spleen HSPCs (Supplementary Figure 4). Finally, to
determine whether TLR2 agonist exposure increases functional HSCs
in the spleen, we transplanted either whole spleen cells or sorted
HSCs into lethally irradiated recipient mice. Transplantation of whole
spleen cells revealed a signiﬁcant increase in total repopulating units
per spleen in agonist-treated mice compared with controls
(Figure 2h). Transplantation of sorted KSL SLAM cells (20 HSCs
(CD45.1) with 3×105 whole marrow support cells (CD45.2) into
irradiated recipients) from the spleens or bone marrow of PAM3CSK4-
Figure 1. TLR2 agonist treatment leads to increased bone marrow phenotypic HSC frequency but loss of bone marrow repopulating activity.
WTmice (6–8 weeks old) were treated with PAM3CSK4 (100 μg intraperitoneally (i.p.) q48 h × 3 doses, analyzed 24 h after ﬁnal dose). Shown are
the frequency (a) and absolute numbers (b) of bone marrow HSPCs as determined by ﬂow cytometry using the gating strategy outlined in
Supplementary Figure 1 (n = 12–13 mice per treatment group). (c) Whole bone marrow from PAM3CSK4-treated mice or water-treated controls
(CD45.1) was transplanted in a 1:1 ratio with untreated competitor bone marrow (CD45.2) into lethally irradiated recipients (CD45.1/CD45.2).
Shown are the frequency of donor cells (CD45.1+ single positive), including overall leukocytes, B cells (B220+), T cells (CD3e+) and neutrophils
(Gr-1 hi), in the peripheral blood of primary recipients over time. (d) At 24 weeks post transplant, bone marrow from primary recipients was
pooled and transplanted into secondary recipients. Shown is the frequency of donor cells (CD45.1+ single positive) in the peripheral blood of
these secondary recipients over time. Data represent 8–12 recipient mice per treatment group from 2 independent experiments. *Po0.05;
**Po0.01. (e) To assess homing, 2 × 106 whole bone marrow cells from PAM3CSK4-treated mice or water controls were transplanted into
lethally irradiated recipients. Shown are the total number of KSL cells detected from the long bones (femurs, tibias, humerii) and pelvis 16 h
later (n= 5 mice per group). For all panels, error bars represent mean± s.e.m., and P-values were determined by the two-tailed Student’s t-test.
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treated mice demonstrated that the spleen KSL SLAM cells have
similar function to bone marrow KSL SLAM cells in PAM3CSK4-treated
mice (Figures 2I and j). Thus, functional HSCs increase in the spleen
upon TLR2 agonist exposure.
TLR2 agonist effects on HSC expansion and function are, at least in
part, cell non-autonomous
As TLR2 is expressed on multiple hematopoietic and stromal
cell populations in addition to HSCs, the effects of systemic
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TLR2 agonist treatment could be either cell autonomous or cell
non-autonomous. A recent study demonstrated that exposure of
mice to a TLR4 ligand mobilizes HSCs in a cell-non-autonomous,
G-CSF-dependent manner.8 To determine whether the effects
of TLR2 signaling are similarly non-autonomous, we generated
chimeric mice in which a 1:1 mixture of Tlr2−/− (CD45.2) and WT
(CD45.1) bone marrow cells were transplanted into WT recipients
(Figure 3a). Chimeras were treated as above with PAM3CSK4, and
HSPCs were analyzed by ﬂow cytometry. In addition, bone marrow
from these mice was transplanted into new irradiated recipients to
assess HSC function. We reasoned that if TLR2 signaling regulates HSCs
in a cell-autonomous manner, we would observe a preferential effect
of agonist treatment on WT cells, whereas if the effects of TLR2
ligation were non-autonomous, we would ﬁnd a similar effect of
treatment on both Tlr2−/− and WT HSCs. Although there was not
a signiﬁcant increase in bone marrow HSCs from either population
in these chimeras (Figures 3b and c), PAM3CSK4 treatment resulted
in a marked increase in both WT and Tlr2−/− HSPCs in the spleen
(Figures 3d and e), suggesting that the spleen expansion is
mediated by extrinsic factors. In fact, we actually saw a preferential
mobilization of Tlr2−/− HSCs in our chimeras. The reason for this
is unclear, however a similar phenomenon was reported for Tlr4−/−
HSCs mobilized by Escherichia coli,8 and we previously found
that Tlr2−/− HSCs mobilize more robustly than WT cells upon
G-CSF exposure, suggesting that they may be more responsive to
mobilizing stimuli.16
To assess whether the loss of bone marrow repopulating activity
is cell autonomous versus non-autonomous, we transplanted
bone marrow from the treated chimeras into new irradiated recipients.
Again, we reasoned that if the effects of TLR2 signaling on
HSC function are cell autonomous, we would observe a preferential
defect in the WT cells (that is, a decrease in %CD45.1 upon
PAM3CSK4 treatment), whereas if the effects of TLR2 ligation are
non-autonomous, we would ﬁnd a similar effect of treatment on
both Tlr2−/− and WT HSCs (that is, no difference in chimerism). Analysis
of the peripheral blood chimerism of these secondary recipients
showed no differences between treatment groups (Supplementary
Figure 5), suggesting that the functional deﬁcit described in Figure 1 is
inﬂuenced by non-autonomous TLR2 signaling. Thus, as the effects of
PAM3CSK4 on HSPCs are observed in cells lacking TLR2 as well as
WT cells, these effects must be, at least in part, cell non-autonomous.
Spleen HSPC expansion upon TLR2 agonist exposure is mediated
by non-autonomous effects of TLR2 signaling in both
radioresistant and radiosensitive cell populations
We next generated chimeras to determine whether stromal versus
hematopoietic TLR2 signaling mediates HSPC expansion. Speciﬁ-
cally, we transplanted WT bone marrow into Tlr2−/− recipients
(WT→ Tlr2−/−), Tlr2−/− marrow into WT recipients (Tlr2−/−→WT) or
WT into WT (WT→WT). We treated the mice with PAM3CSK4
as before and assessed bone marrow and spleen HSPCs by ﬂow
cytometry. We observed a nonsigniﬁcant trend toward increased
HSC frequency only in cases where hematopoietic cells expressed
TLR2 (WT→WT and WT→ Tlr2−/−; Figure 4a); however, spleen
HSPCs increased in all three chimeric groups (Figures 4b and c),
suggesting that TLR2 expression on either radioresistant (that is,
mostly stromal) or radiosensitive (hematopoietic) cells is sufﬁcient
to induce some mobilization (or expansion) of spleen HSPCs.
TLR2 agonist treatment leads to G-CSF production by both
radioresistant and radiosensitive cell populations
To identify potential mediators of the cell-non-autonomous effects
of TLR2 signaling on HSPCs, we performed cytokine arrays on WT
mouse serum, bone marrow and spleen after systemic treatment
with PAM3CSK4. Serum levels of G-CSF, CXCL13, IP-10/CXCL10
and monocyte chemoattractant protein (MCP-1/CCL2) were the
most markedly increased in treated mice compared with controls
(Supplementary Figure 6). As noted above, recent reports have
demonstrated that the TLR4 ligand lipopolysaccharide induces
G-CSF production from endothelial cells, and G-CSF mediates
the mobilization of HSCs in response to lipopolysaccharide.8,9 We
therefore ﬁrst considered that G-CSF may similarly mediate HSC
mobilization in response to TLR2 agonist. Indeed, PAM3CSK4 exposure
is associated with a dose-dependent increase in serum G-CSF
(Figure 5a). Furthermore, we observed an increase in serum G-CSF in
all of our chimeras (WT→WT, WT→Tlr2−/− and Tlr2−/−→WT), but not
in parent Tlr2−/− mice (Figure 5b), suggesting that both radioresistant
and radiosensitive cell populations serve as sources of this cytokine.
Suppression of G-CSF signaling partially mitigates the effects
of TLR2 agonist exposure on HSPCs
To assess the contribution of G-CSF signaling to the effects of TLR2
agonist treatment on HSCs, we treated mice lacking the G-CSF
receptor (Csf3r−/− mice) with PAM3CSK4. Although bone marrow
HSCs expanded in response to PAM3CSK4 in the absence of G-CSF
signaling (Figures 5c and d), loss of this signaling leads to a modest
reduction in spleen myeloid progenitor cell expansion, speciﬁcally
resulting in reduced expansion of spleen common myeloid
progenitors, granulocyte–monocyte progenitors and myeloid pro-
genitor colony-forming units in response to PAM3CSK4 compared
with WT (Figure 5f and Supplementary Figure 7). A similar reduction
in PAM3CSK4-mediated spleen myeloid progenitor expansion was
observed when WT mice were treated with a G-CSF neutralizing
antibody (Supplementary Figure 7). Of note, we still observed
a signiﬁcant increase in spleen HSCs and progenitors in the absence
of G-CSF signaling (Figure 5e and Supplementary Figure 7),
suggesting that G-CSF is not the sole mediator of this increase.
Figure 2. TLR2 agonist treatment leads to marked expansion of spleen HSPCs. WT mice (6–8 weeks old) were treated with PAM3CSK4 (100 μg
intraperitoneally (i.p.) q48 h × 3 doses, analyzed 24 h after ﬁnal dose). (a) Representative spleens from control water-treated (left) and
PAM3CSK4-treated (right) mice. Shown are the total leukocytes per spleen (b) and the frequency (c) and absolute numbers (d) of KSL SLAM
cells, common myeloid progenitors (CMPs), granulocyte–monocyte progenitors (GMPs) and megakaryocyte–erythroid progenitors (MEPs) in
the spleen as determined by ﬂow cytometry (n= 11–13 mice per treatment group). The cell cycle status of KSL SLAM cells in the bone marrow
and spleen was determined by ﬂow cytometry using Ki-67 and DAPI (e) or BrdU incorporation (f) (n= 7–10 mice per group). (g) Whole spleen
cells from PAM3CSK4-treated mice or water-treated controls were plated on complete methylcellulose, and colonies counted after 7 days of
growth at 37 °C (n= 7 mice per group). (h) To determine HSC function, 2 × 106 whole spleen cells (CD45.1) from control or PAM3CSK4-treated
mice were transplanted along with 1× 106 whole bone marrow competitor cells (CD45.2) into lethally irradiated WT recipients (CD45.1/
CD45.2). Shown are total repopulating units per spleen at 18 weeks post transplant. Repopulating units were determined using the equation
RU= ([% chimerism of test donor-derived cells] × [no. of competitor cells] × 10− 5)/% chimerism of competitor-derived cells. The result was
then multiplied by total spleen WBCs to obtain RUs/spleen. Data represent seven mice per treatment group from two independent
experiments. (i, j) Twenty KSL SLAM HSCs (CD45.1) from the spleens or bone marrow of PAM3CSK4-treated mice were transplanted with 3 × 10
5
whole marrow support cells (CD45.2) into irradiated recipients. Shown are % donor (CD45.1) leukocytes in the recipients (i) and % of recipients
with multilineage (⩾1% in myeloid and lymphoid lineages) donor (CD45.1) engraftment (j). Data represent 11–12 mice per group from 3
independent experiments. For all panels, error bars represent mean± s.e.m.. Data in (i and j) were analyzed by two-way analysis of variance
(ANOVA) with multiple comparisons, and all other P-values were determined by two-tailed Student’s t-test.
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In fact, transplantation of whole spleen cells from mice treated with
PAM3CSK4 and G-CSF neutralizing antibody revealed no loss of total
spleen repopulating units (Supplementary Figure 7).
Cell-autonomous TLR2 signaling contributes to spleen HSC
expansion
As G-CSF only partially accounts for the expansion of spleen
HSPCs in response to PAM3CSK4, other extrinsic factors, or
cell-autonomous TLR2 signaling, must account for the remain-
ing increase. To address whether there is a cell-autonomous
component to this expansion, we treated chimeric mice (WT+Tlr2−/−
bone marrow transplanted into Tlr2−/− recipients, Figure 6a) with
PAM3CSK4 and a G-CSF neutralizing antibody, thus minimizing the
effects of G-CSF. Again, we see expansion of both WT and Tlr2−/−
HSPCs in the spleen (Figure 6b), supporting a role for G-CSF-
independent, hematopoietic-mediated non-autonomous TLR2 sig-
naling in this process. However, we observed a relatively greater
Figure 3. TLR2 agonist effects on HSPCs are, at least in part, cell non-autonomous. (a) Chimeric animals were generated by transplanting equal
numbers of WT (CD45.1) and Tlr2−/− (CD45.2) bone marrow cells into lethally irradiated WT (CD45.1/CD45.2) recipients. After allowing time
for engraftment (12 weeks), recipients were treated with PAM3CSK4 (100 μg intraperitoneally (i.p.) q48 h × 3 doses) and the relative frequencies
(b, d) and absolute numbers (c, e) of HSPCs in the bone marrow (b, c) and spleen (d, e) were determined by ﬂow cytometry. (b) The frequency
of WT (CD45.1) HSPCs for each indicated cell type in the bone marrow after treatment is shown. (c) Absolute numbers of cells per femur after
treatment of chimeras is shown. Dark bars indicate WT (CD45.1) cells, and light bars indicate Tlr2−/− (CD45.2) cells. Solid bars indicate water-
treated controls, and hatched bars indicate PAM3CSK4-treated mice (n = 10 mice per treatment group). (d) The frequency of WT (CD45.1)
HSPCs for each indicated cell type in the spleen after treatment is shown. (e) Absolute numbers of cells per spleen after treatment of chimeras
is shown. Dark bars indicate WT (CD45.1) cells, and light bars indicate Tlr2−/− (CD45.2) cells. Solid bars indicate water-treated controls,
and hatched bars indicate PAM3CSK4-treated mice (n= 10 mice per treatment group). For all panels, error bars represent mean± s.e.m., and
P-values were determined by the two-tailed Student’s t-test.
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Figure 4. The effects of TLR2 agonist exposure are mediated by non-autonomous TLR2 signaling in both radioresistant and radiosensitive
populations. Chimeric mice were generated by transplanting WT bone marrow into WT recipients (WT→WT), Tlr2−/− bone marrow into WT
recipients (Tlr2−/−→WT) and WT bone marrow into Tlr2−/− recipients (WT→ Tlr2−/−). After allowing time for engraftment (11 weeks), mice
were treated with PAM3CSK4 (100 μg intraperitoneally (i.p.) q48 h × 3 doses). Shown are KSL SLAM frequency in the bone marrow (a) and KSL
SLAM cells per spleen (b), as determined by ﬂow cytometry, in chimeric mice and in constitutional Tlr2−/− controls. (c) Spleen cells from
chimeric mice and constitutional Tlr2−/− controls were plated in complete methylcellulose media and myeloid colony formation was scored
after 7 days of growth at 37 °C (n= 3–4 mice per group). For all panels, error bars represent mean± s.e.m., and P-values were determined by
the two-tailed Student’s t-test.
Figure 5. G-CSF production partially accounts for the effects of TLR2 agonist exposure on HSPCs. (a) WT mice (6–8 weeks old) were given a
single intraperitoneal (i.p.) injection of PAM3CSK4 at the indicated doses, and serum G-CSF levels were determined by ELISA 12 h later (n= 4–6
mice per treatment level). (b) Chimeric mice as described in Figure 4 were given a single i.p. injection of 100 μg PAM3CSK4, and serum G-CSF
levels were determined by ELISA (n= 3 mice per group, with the exception of the water group (n= 9) that represents pooled controls from all
of the treatment groups. (c) WT or Csf3r−/− mice were treated with PAM3CSK4 (100 μg i.p. q48 h × 3 doses, analyzed 24 h after ﬁnal dose).
Shown are the frequency (c) and absolute numbers (d) of KSL SLAM cells in the bone marrow. Also shown are KSL SLAM cells per spleen (e).
(f) Whole spleen cells from PAM3CSK4-treated mice or water-treated controls were plated on complete methylcellulose, and colonies counted
after 7 days of growth at 37 °C (n= 6–7 mice per group). For all panels, error bars represent mean± s.e.m., and P-values were determined by
the two-tailed Student’s t-test.
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expansion of WT HSCs compared with Tlr2−/− HSCs (Figure 6c),
suggesting that cell-autonomous TLR2 signaling contributes to
HSC expansion. Thus, although PAM3CSK4 clearly affects cells
lacking TLR2 (reﬂecting indirect, or cell-non-autonomous effects),
the more robust expansion of WT cells compared with Tlr2−/− cells
in this experiment demonstrates that cell-autonomous signaling
also contributes to this effect of PAM3CSK4 on HSCs.
TNFα contributes to the TLR2 agonist-mediated expansion of
HSPCs in the spleen
We next considered whether the other cytokines elevated upon
PAM3CSK4 treatment contribute to the remaining non-autonomous
effects of TLR2 signaling on HSCs (Supplementary Figure 6). To this
end, we assessed the response of Ccl2− /− , Cxcr5− /− (CXCR5 is
the receptor for CXCL13), IFNγ− /− and TNFα− /− mice to PAM3CSK4
exposure. We assessed a small number of Cxcl10−/− mice as well
with no obvious difference in TLR2- mediated effects from WT
(data not shown). As CXCL10 is regulated by interferon-γ (IFNγ) and
TNFα, and these cytokines can regulate HSCs,21–23 we tested their
contribution as well (in fact, serum TNFα levels increased by ELISA
upon PAM3CSK4 treatment; Supplementary Figure 8). Notably,
loss of TNFα results in a signiﬁcant decrease in the magnitude of
the PAM3CSK4- mediated expansion of spleen HSCs and progenitors
compared with WT (Figures 7b and c and Supplementary Figure 8),
and spleen HSC cycling in response to the TLR2 agonist is mitigated
in the absence of TNFα (Figure 7d). Furthermore, treatment of
mice with neutralizing antibodies to both G-CSF and TNFα before
PAM3CSK4 injection reduced the expansion of HSCs in the spleen by
nearly threefold, and markedly decreased spleen common myeloid
progenitors, granulocyte–monocyte progenitors and progenitor
colony-forming units (Figures 7e–g and Supplementary Figure 8),
further implicating these cytokines as regulators of spleen HSPC
mobilization/expansion in response to TLR2 ligand.
DISCUSSION
Although multiple TLRs are expressed on HSCs, most notably TLR2
and TLR4,10 most of the published studies have focused on
the effects of TLR4 stimulation on HSCs. We recently reported
that TLR2 is not necessary to maintain normal HSC function,16 and
herein we sought to determine the effects of systemic TLR2 ligand
exposure on HSCs. Our data demonstrate that indeed TLR2
stimulation affects HSC expansion and function, and suggest that
these effects are mediated by both cell-autonomous and cell-non-
autonomous mechanisms.
Recent studies have shown that exposure of mice to systemic
TLR4 ligands leads to HSC expansion and mobilization, and a loss of
bone marrow HSC function.4,5,8,24,25 Mechanistic studies indicate
that TLR4 stimulation leads to G-CSF production from endothelial
cells,9 and G-CSF signaling blockade abrogates TLR4-induced HSC
accumulation in the spleen.8 Like TLR4, stimulation of TLR2 leads to
HSPC expansion, loss of HSC function and G-CSF production.
However, in response to TLR2 agonist, G-CSF is produced from
both radioresistant and radiosensitive populations, suggesting it is
not primarily endothelial in origin. In addition, suppression of G-CSF
signaling only partly mitigates the expansion of myeloid progenitors
in the spleen and does not signiﬁcantly affect HSCs. Further studies
demonstrated that TNFα contributes to the cell-non-autonomous
effects of TLR2 agonist exposure on HSPCs. The identity of the cell
types that mediate these non-autonomous effects await further
studies using mice with conditional deletion of TLR2.
Our chimeric animal studies with G-CSF inhibition also support a
role for cell-autonomous TLR2 signaling in the expansion of
HSCs. Megias et al.26 previously demonstrated that puriﬁed WT
c-Kit+ Sca-1+ Lineage − HSPCs transferred into Tlr2−/−-deﬁcient
recipients differentiate into macrophages in response to short-
term treatment with PAM3CSK4, suggesting that HSPCs can
directly responding to TLR signals in vivo. Joo et al.27 similarly
demonstrated that WT c-Kit+ Lineage− HSPCs transplanted into
Tlr2−/−-deﬁcient mice differentiated into myeloid lineage cells
in response to TLR2 agonist. Together with prior in vitro studies
Figure 6. Cell-autonomous TLR2 signaling contributes to
PAM3CSK4-mediated HSC expansion. (a) Chimeric animals were
generated by transplanting equal numbers of WT (CD45.1) and
Tlr2−/− (CD45.2) bone marrow cells into lethally irradiated Tlr2−/−
(CD45.2) recipients. (b) After allowing time for engraftment
(12 weeks), recipients were treated with PAM3CSK4 (100 μg
intraperitoneally (i.p.) q48 h × 3 doses) and a G-CSF neutralizing
antibody and the absolute numbers of KSL SLAM, common
myeloid progenitor (CMP), granulocyte–monocyte progenitor
(GMP) and megakaryocyte–erythroid progenitor (MEP) cells
per spleen for each donor cell type were determined by ﬂow
cytometry. Shown are cells/spleen for the indicated populations.
Dark bars indicate WT (CD45.1) cells, and light bars indicate
Tlr2−/− (CD45.2) cells. Solid bars indicate water-treated controls,
and hatched bars indicate PAM3CSK4-treated mice. (c) The relative
frequencies of wild-type donor (CD45.1) HSPCs are shown
for PAM3CSK4-treated or water control-treated chimeric mice.
Data represent three chimeras from each treatment group from
three separate experiments, and P-values were determined by
two-tailed Student’s t-test. Error bars represent mean± s.e.m.
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demonstrating that TLR2 stimulation directs myeloid differentia-
tion of HSPCs,1,3 our data reinforce the idea that TLR2 agonists
have cell-autonomous effects on HSCs. These data highlight
an important point that the effects of TLR signals on HSCs may
differ depending on the particular agonist/TLR, with TLR4 signals
exerting largely G-CSF-dependent, non-cell-autonomous effects
on HSCs and TLR2 signals exerting primarily TNFα-dependent
effects, with a more minor contribution from G-CSF and cell-
autonomous effects.
Interestingly, we ﬁnd that, unlike bone marrow HSCs, spleen
HSCs are signiﬁcantly less quiescent upon TLR2 ligand exposure.
Thus, in contrast to the primarily mobilization-mediated increase
in spleen HSCs upon TLR4 ligation,8 TLR2 signaling appears to
stimulate local proliferation of spleen HSCs. This TLR2 agonist-
induced spleen HSC cycling is lost in TNFα− /− mice, implicating
TNFα in this process. The biologic signiﬁcance of this local
proliferation and the reason for the differential effects of TLR2
agonist exposure on the cycling of bone marrow versus spleen
Figure 7. TNFα contributes to PAM3CSK4-mediated spleen HSPC expansion. WT, TNFα− /− , Ccl2− /− , Cxcr5− /− and IFNγ− /− mice (6–8 weeks old)
were treated with PAM3CSK4 (100 μg intraperitoneally (i.p.) q48 h ×3 doses, analyzed 24 h after ﬁnal dose) or water alone. Shown are the KSL
SLAM cells per femur (a) and spleen (b). (c) Whole spleen cells from PAM3CSK4-treated mice or water-treated controls were plated on complete
methylcellulose, and colonies counted after 7 days of growth at 37 °C. (d) Following PAM3CSK4 treatment, the cell cycle status of KSL SLAM cells in
the spleen of mice of the indicated genotypes were determined by ﬂow cytometry using Ki-67 and DAPI. (n= 4–12 mice per group). (e–g) WT
mice were treated with PAM3CSK4 as described above, and in addition some mice received G-CSF and TNFα neutralizing antibodies or isotype
control antibody before PAM3CSK4 injections. KSL SLAM cells in the bone marrow (e) and spleen (f) were determined by ﬂow cytometry. In
addition, whole spleen cells were plated on complete methylcellulose, and colonies counted after 7 days of growth at 37 °C (g); n= 5–6 mice per
group. For all panels, error bars represent mean± s.e.m., and P-values were determined by the two-tailed Student’s t-test.
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HSCs is not known. Of note, Granick et al.28 recently reported
that proliferation of HSPCs in skin wounds in response to the
TLR2 agonist Staphylococcus aureus contributes signiﬁcantly
to the production of neutrophils and resolution of local infection,
supporting a role for TLR2 signaling in the regulation of
extramedullary hematopoiesis.
The accumulating data on TLR agonist effects on HSCs suggest
that TLR signals may, in the short term, inﬂuence HSC proliferation
and differentiation to optimize the immune response to an acute
insult. In theory, enhanced cycling, mobilization and differentia-
tion of HSCs during acute infection could help to ensure that
the proper cadre of effector cells are produced to eliminate the
offending stimulus. Chronic or aberrant exposure to these signals,
however, may lead to dysfunctional hematopoiesis and contribute
to bone marrow failure or malignancy. Enhanced TLR2 signaling
has recently been implicated in MDS.15 Our data support a role
for TLR2 signaling in the regulation of HSCs, with agonist exposure
leading to expansion of HSCs in the bone marrow and spleen,
but a reduction in HSC self-renewal. These ﬁndings suggest the
possibility that enhanced TLR2 signaling may contribute to the
ineffective hematopoiesis characteristic of MDS. The role of TLR2
signaling in this disease and the contribution of TLR2 signaling
from different cell types to the effects of TLR2 agonist exposure on
normal and premalignant HSCs awaits further study.
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